AU2013353957B2 - Protein slurp-1 for use in the treatment of ocular diseases - Google Patents
Protein slurp-1 for use in the treatment of ocular diseases Download PDFInfo
- Publication number
- AU2013353957B2 AU2013353957B2 AU2013353957A AU2013353957A AU2013353957B2 AU 2013353957 B2 AU2013353957 B2 AU 2013353957B2 AU 2013353957 A AU2013353957 A AU 2013353957A AU 2013353957 A AU2013353957 A AU 2013353957A AU 2013353957 B2 AU2013353957 B2 AU 2013353957B2
- Authority
- AU
- Australia
- Prior art keywords
- cys
- protein
- thr
- ser
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 37
- 208000022873 Ocular disease Diseases 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 12
- 102100038583 Secreted Ly-6/uPAR-related protein 1 Human genes 0.000 claims abstract description 4
- 101710127389 Secreted Ly-6/uPAR-related protein 1 Proteins 0.000 claims abstract 3
- 230000035876 healing Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 238000002347 injection Methods 0.000 claims description 20
- 239000007924 injection Substances 0.000 claims description 20
- 206010052428 Wound Diseases 0.000 claims description 18
- 208000027418 Wounds and injury Diseases 0.000 claims description 17
- 230000000699 topical effect Effects 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 229920000249 biocompatible polymer Polymers 0.000 claims description 8
- 229920002307 Dextran Polymers 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002000 Xyloglucan Polymers 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 108010093581 aspartyl-proline Proteins 0.000 claims 2
- 108010004073 cysteinylcysteine Proteins 0.000 claims 2
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 claims 1
- JQDFGZKKXBEANU-IMJSIDKUSA-N Ala-Cys Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(O)=O JQDFGZKKXBEANU-IMJSIDKUSA-N 0.000 claims 1
- KMGOBAQSCKTBGD-DLOVCJGASA-N Ala-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CN=CN1 KMGOBAQSCKTBGD-DLOVCJGASA-N 0.000 claims 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 claims 1
- YNOCMHZSWJMGBB-GCJQMDKQSA-N Ala-Thr-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O YNOCMHZSWJMGBB-GCJQMDKQSA-N 0.000 claims 1
- ZCUFMRIQCPNOHZ-NRPADANISA-N Ala-Val-Gln Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N ZCUFMRIQCPNOHZ-NRPADANISA-N 0.000 claims 1
- SVHRPCMZTWZROG-DCAQKATOSA-N Arg-Cys-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCN=C(N)N)N SVHRPCMZTWZROG-DCAQKATOSA-N 0.000 claims 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 claims 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 claims 1
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 claims 1
- KUYKVGODHGHFDI-ACZMJKKPSA-N Asn-Gln-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O KUYKVGODHGHFDI-ACZMJKKPSA-N 0.000 claims 1
- AITKTFCQOBRJTG-CIUDSAMLSA-N Asp-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N AITKTFCQOBRJTG-CIUDSAMLSA-N 0.000 claims 1
- DRCOAZZDQRCGGP-GHCJXIJMSA-N Asp-Ser-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DRCOAZZDQRCGGP-GHCJXIJMSA-N 0.000 claims 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 claims 1
- BNCKELUXXUYRNY-GUBZILKMSA-N Cys-Lys-Glu Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N BNCKELUXXUYRNY-GUBZILKMSA-N 0.000 claims 1
- XMVZMBGFIOQONW-GARJFASQSA-N Cys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N)C(=O)O XMVZMBGFIOQONW-GARJFASQSA-N 0.000 claims 1
- YNJBLTDKTMKEET-ZLUOBGJFSA-N Cys-Ser-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O YNJBLTDKTMKEET-ZLUOBGJFSA-N 0.000 claims 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 claims 1
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 claims 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 claims 1
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 claims 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 claims 1
- FXLVSYVJDPCIHH-STQMWFEESA-N Gly-Phe-Arg Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FXLVSYVJDPCIHH-STQMWFEESA-N 0.000 claims 1
- MMFKFJORZBJVNF-UWVGGRQHSA-N His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MMFKFJORZBJVNF-UWVGGRQHSA-N 0.000 claims 1
- KTTMFLSBTNBAHL-MXAVVETBSA-N Ile-Phe-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N KTTMFLSBTNBAHL-MXAVVETBSA-N 0.000 claims 1
- 108010065920 Insulin Lispro Proteins 0.000 claims 1
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 claims 1
- QONKWXNJRRNTBV-AVGNSLFASA-N Leu-Pro-Met Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)O)N QONKWXNJRRNTBV-AVGNSLFASA-N 0.000 claims 1
- DZQYZKPINJLLEN-KKUMJFAQSA-N Lys-Cys-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N)O DZQYZKPINJLLEN-KKUMJFAQSA-N 0.000 claims 1
- RMOKGALPSPOYKE-KATARQTJSA-N Lys-Thr-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMOKGALPSPOYKE-KATARQTJSA-N 0.000 claims 1
- STLBOMUOQNIALW-BQBZGAKWSA-N Met-Gly-Cys Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](CS)C(O)=O STLBOMUOQNIALW-BQBZGAKWSA-N 0.000 claims 1
- QYIGOFGUOVTAHK-ZJDVBMNYSA-N Met-Thr-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QYIGOFGUOVTAHK-ZJDVBMNYSA-N 0.000 claims 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 claims 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 claims 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 claims 1
- QGLFRQCECIWXFA-RCWTZXSCSA-N Pro-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1)O QGLFRQCECIWXFA-RCWTZXSCSA-N 0.000 claims 1
- FFOKMZOAVHEWET-IMJSIDKUSA-N Ser-Cys Chemical compound OC[C@H](N)C(=O)N[C@@H](CS)C(O)=O FFOKMZOAVHEWET-IMJSIDKUSA-N 0.000 claims 1
- BLPYXIXXCFVIIF-FXQIFTODSA-N Ser-Cys-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N)CN=C(N)N BLPYXIXXCFVIIF-FXQIFTODSA-N 0.000 claims 1
- SWIQQMYVHIXPEK-FXQIFTODSA-N Ser-Cys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O SWIQQMYVHIXPEK-FXQIFTODSA-N 0.000 claims 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 claims 1
- CKDXFSPMIDSMGV-GUBZILKMSA-N Ser-Pro-Val Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O CKDXFSPMIDSMGV-GUBZILKMSA-N 0.000 claims 1
- YRNBANYVJJBGDI-VZFHVOOUSA-N Thr-Ala-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CS)C(=O)O)N)O YRNBANYVJJBGDI-VZFHVOOUSA-N 0.000 claims 1
- BWUHENPAEMNGQJ-ZDLURKLDSA-N Thr-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O BWUHENPAEMNGQJ-ZDLURKLDSA-N 0.000 claims 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 claims 1
- PRNGXSILMXSWQQ-OEAJRASXSA-N Thr-Leu-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PRNGXSILMXSWQQ-OEAJRASXSA-N 0.000 claims 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 claims 1
- RCMWNNJFKNDKQR-UFYCRDLUSA-N Tyr-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 RCMWNNJFKNDKQR-UFYCRDLUSA-N 0.000 claims 1
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 claims 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 claims 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 claims 1
- 108010041407 alanylaspartic acid Proteins 0.000 claims 1
- 108010016616 cysteinylglycine Proteins 0.000 claims 1
- 108010025306 histidylleucine Proteins 0.000 claims 1
- 108010034529 leucyl-lysine Proteins 0.000 claims 1
- 108010009298 lysylglutamic acid Proteins 0.000 claims 1
- 108010026333 seryl-proline Proteins 0.000 claims 1
- 108010020532 tyrosyl-proline Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 19
- 210000004087 cornea Anatomy 0.000 description 16
- 230000029663 wound healing Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 230000003902 lesion Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 7
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 7
- 241000270295 Serpentes Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100038579 Secreted Ly-6/uPAR domain-containing protein 2 Human genes 0.000 description 5
- 101710171964 Secreted Ly-6/uPAR domain-containing protein 2 Proteins 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002581 neurotoxin Substances 0.000 description 5
- 231100000618 neurotoxin Toxicity 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- 230000004453 corneal transparency Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000837 Heparan sulfate analogue Polymers 0.000 description 2
- 101001065559 Homo sapiens Lymphocyte antigen 6D Proteins 0.000 description 2
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 2
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000037309 reepithelialization Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000036086 Chromosome Duplication Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 206010015911 Eye burns Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101001065554 Homo sapiens Lymphocyte antigen 6H Proteins 0.000 description 1
- 101000664418 Homo sapiens Secreted Ly-6/uPAR-related protein 1 Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102100032127 Lymphocyte antigen 6D Human genes 0.000 description 1
- 102100032128 Lymphocyte antigen 6H Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 101001065558 Mus musculus Lymphocyte antigen 6E Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000532838 Platypus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196007.4 | 2012-12-07 | ||
| EP12196007.4A EP2740485B1 (en) | 2012-12-07 | 2012-12-07 | Protein slurp-1 for use in the treatment of ocular diseases |
| PCT/EP2013/075981 WO2014087022A1 (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2013353957A1 AU2013353957A1 (en) | 2015-05-28 |
| AU2013353957B2 true AU2013353957B2 (en) | 2018-05-17 |
Family
ID=47297008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013353957A Ceased AU2013353957B2 (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10098925B2 (https=) |
| EP (1) | EP2740485B1 (https=) |
| JP (1) | JP6335188B2 (https=) |
| KR (1) | KR20150108351A (https=) |
| CN (1) | CN105188731B (https=) |
| AU (1) | AU2013353957B2 (https=) |
| BR (1) | BR112015013215A2 (https=) |
| CA (1) | CA2891201A1 (https=) |
| CL (1) | CL2015001520A1 (https=) |
| EA (1) | EA201591095A1 (https=) |
| IL (1) | IL239078A0 (https=) |
| MX (1) | MX2015006779A (https=) |
| SG (2) | SG10201705592YA (https=) |
| WO (1) | WO2014087022A1 (https=) |
| ZA (1) | ZA201503747B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
| EP3689327B1 (fr) * | 2019-01-24 | 2025-03-12 | Organes Tissus Régénération Réparation Remplacement | Composition pharmaceutique dans le traitement de lésions pulmonaires |
| CN114601915B (zh) * | 2022-03-25 | 2023-04-07 | 四川大学华西医院 | Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014959A1 (en) * | 1992-12-22 | 1994-07-07 | Applied Research Systems Ars Holding N.V. | New protein from urine named component b |
| WO2004091646A2 (en) * | 2003-04-16 | 2004-10-28 | Applied Research Systems Ars Holding, N.V. | Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
| WO2010138379A2 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using galanin retargeted endopeptidases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2806143A1 (en) * | 2010-07-30 | 2012-02-02 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H | Drug delivery devices and growth factor formulations for accelerated wound healing |
| EP3848055A1 (en) * | 2011-06-03 | 2021-07-14 | Ophidion Inc. | Compositions and methods for transport across the blood brain barrier |
| US9132193B2 (en) * | 2012-11-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of Slurp1 as an imunomodulatory molecule in the ocular surface |
| CA2890424C (en) * | 2012-11-08 | 2020-11-17 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
| EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
-
2012
- 2012-12-07 EP EP12196007.4A patent/EP2740485B1/en not_active Not-in-force
-
2013
- 2013-12-09 CA CA2891201A patent/CA2891201A1/en not_active Abandoned
- 2013-12-09 WO PCT/EP2013/075981 patent/WO2014087022A1/en not_active Ceased
- 2013-12-09 MX MX2015006779A patent/MX2015006779A/es unknown
- 2013-12-09 CN CN201380064175.2A patent/CN105188731B/zh not_active Expired - Fee Related
- 2013-12-09 SG SG10201705592YA patent/SG10201705592YA/en unknown
- 2013-12-09 EA EA201591095A patent/EA201591095A1/ru unknown
- 2013-12-09 KR KR1020157015595A patent/KR20150108351A/ko not_active Withdrawn
- 2013-12-09 BR BR112015013215A patent/BR112015013215A2/pt not_active IP Right Cessation
- 2013-12-09 US US14/650,277 patent/US10098925B2/en not_active Expired - Fee Related
- 2013-12-09 AU AU2013353957A patent/AU2013353957B2/en not_active Ceased
- 2013-12-09 SG SG11201503658XA patent/SG11201503658XA/en unknown
- 2013-12-09 JP JP2015546050A patent/JP6335188B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-26 ZA ZA2015/03747A patent/ZA201503747B/en unknown
- 2015-05-28 IL IL239078A patent/IL239078A0/en unknown
- 2015-06-04 CL CL2015001520A patent/CL2015001520A1/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994014959A1 (en) * | 1992-12-22 | 1994-07-07 | Applied Research Systems Ars Holding N.V. | New protein from urine named component b |
| WO2004091646A2 (en) * | 2003-04-16 | 2004-10-28 | Applied Research Systems Ars Holding, N.V. | Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
| WO2010138379A2 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of treating chronic neurogenic inflammation using galanin retargeted endopeptidases |
Non-Patent Citations (3)
| Title |
|---|
| ALEXANDER I. CHERNYAVSKY ET AL, (2012-01-01), vol. 20, no. 1, doi:10.1111/j.1524-475X.2011.00753.x, ISSN 1067-1927, pages 103 - 113 * |
| ELDER MARK J ET AL, "Progression of disease in ocular cicatricial pemphigoid", BRITISH JOURNAL OF OPHTHALMOLOGY, (1996), vol. 80, no. 4, ISSN 0007-1161, pages 292 - 296 * |
| SWAMYNATHAN SUDHA ET AL, "Klf4 Regulates the Expression of Slurp1, Which Functions as an Immunomodulatory Peptide in the Mouse Cornea", IOVS, (2012-11-08), vol. 53, no. 13, pages 8433 - 8446 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL239078A0 (en) | 2015-07-30 |
| EP2740485A1 (en) | 2014-06-11 |
| SG11201503658XA (en) | 2015-06-29 |
| CN105188731B (zh) | 2019-02-05 |
| SG10201705592YA (en) | 2017-08-30 |
| BR112015013215A2 (pt) | 2018-02-06 |
| CN105188731A (zh) | 2015-12-23 |
| CA2891201A1 (en) | 2014-06-12 |
| EP2740485B1 (en) | 2018-10-31 |
| ZA201503747B (en) | 2016-03-30 |
| AU2013353957A1 (en) | 2015-05-28 |
| CL2015001520A1 (es) | 2016-05-20 |
| US20150320831A1 (en) | 2015-11-12 |
| JP2016502558A (ja) | 2016-01-28 |
| EA201591095A1 (ru) | 2015-11-30 |
| KR20150108351A (ko) | 2015-09-25 |
| WO2014087022A1 (en) | 2014-06-12 |
| MX2015006779A (es) | 2015-10-29 |
| US10098925B2 (en) | 2018-10-16 |
| JP6335188B2 (ja) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2705211C2 (ru) | Композиция и способ лечения кожных рубцов | |
| KR102412659B1 (ko) | Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물 | |
| EP2508196B1 (en) | Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing | |
| JP6416240B2 (ja) | 種々の皮膚症状の処置に有用なヒトｃ−ｘ−ｃケモカイン由来テトラペプチド | |
| US5155038A (en) | Use of thrombospondin to promote wound healing | |
| CN105120884B (zh) | 用于促进伤口愈合的短生物活性肽 | |
| CN107252478A (zh) | 弹性纤维的体内合成 | |
| TR201809034T4 (tr) | Biyo-rejeneratif, restoratif ve ötrofik aktiviteye sahip bileşim. | |
| KR20080031405A (ko) | 상피 재생의 촉진 | |
| AU2013353957B2 (en) | Protein slurp-1 for use in the treatment of ocular diseases | |
| CN111420023B (zh) | 含i型胶原和透明质酸的复合物及制备和用途 | |
| Leibowitz et al. | Effect of topically administered epidermal growth factor on corneal wound strength | |
| BRPI0720874B1 (pt) | composições compreendendo peptídeos bioativos curtos para modulação celular e imunológica | |
| CN115991758B (zh) | 一种促进糖尿病创面愈合的珍珠粉多肽及其应用 | |
| TW201204384A (en) | Lactoferrin sequences, compositions and methods of wound treatment | |
| ES2475243T3 (es) | Uso del pentap�ptido PHSRN en formulaciones oft�lmicas | |
| CN111346217B (zh) | 多肽tdl23的新用途 | |
| EP3893920B1 (en) | Composition for the treatment of skin lesions | |
| WO2020037714A1 (zh) | Trail突变体在制备治疗痤疮药物中的应用及一种制剂 | |
| Mao et al. | Bioactive thermoresponsive fibronectin–Pluronic F127 hydrogel for sustained ocular delivery with corneal regeneration and anti-inflammatory effects | |
| Elkhawaga et al. | Assessment of Corneal Epithelial Healing Rate after Pterygium Excision When Using 2% Hyaluronic Acid. | |
| US20240207373A1 (en) | Cyclic peptides from the c-terminus of acetylcholinesterase for treatment of skin disorders and for cosmetical use | |
| JP2025542389A (ja) | 創傷治癒および損傷神経の修復のための組成物および方法 | |
| HK40091784A (zh) | 治疗伤口的组合物和方法 | |
| CN116685344A (zh) | 治疗伤口的组合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |